001     163395
005     20250411160042.0
024 7 _ |a 10.3238/arztebl.m2021.0251
|2 doi
024 7 _ |a pmid:34158150
|2 pmid
024 7 _ |a pmc:PMC8830351
|2 pmc
024 7 _ |a altmetric:108069896
|2 altmetric
037 _ _ |a DZNE-2022-00157
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Klopstock, Thomas
|0 P:(DE-2719)2810704
|b 0
|e First author
|u dzne
245 _ _ |a Mitochondrial Disorders.
260 _ _ |a Köln
|c 2021
|b Dt. Ärzte-Verl.
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1744379990_9891
|2 PUB:(DE-HGF)
|x Review Article
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a Mitochondrial disorders are among the most common heritable diseases, with an overall lifetime risk of approximately one in 1500. Nonetheless, their diagnosis is often missed because of their extreme phenotypic and genotypic heterogeneity.This review is based on publications retrieved by a selective literature search on the clinical features, genetics, pathogenesis, diagnosis, and treatment of mitochondrial diseases.Pathogenic defects of energy metabolism have been described to date in over 400 genes. Only a small number of these genes lie in the mitochondrial DNA; the corresponding diseases are either maternally inherited or of sporadic distribution. The remaining disease-associated genes are coded in nuclear DNA and cause diseases that are inherited according to Mendelian rules, mostly autosomal recessive. The most severely involved organs are generally those with the highest energy requirements, including the brain, the sensory epithelia, and the extraocular, cardiac, and skeletal musculature. Typical manifestations include epileptic seizures, stroke-like episodes, hearing loss, retinopathy, external ophthalmoparesis, exercise intolerance, and diabetes mellitus. More than two manifestations of these types should arouse suspicion of a disease of energy metabolism. The severity of mitochondrial disorders ranges from very severe disease, already evident in childhood, to relatively mild disease arising in late adulthood. The diagnosis is usually confirmed with molecular-genetic methods. Symptomatic treatment can improve patients' quality of life. The only disease-modifying treatment that has been approved to date is idebenone for the treatment of Leber hereditary optic neuropathy. Intravitreal gene therapy has also been developed for the treatment of this disease; its approval by the European Medicines Agency is pending.Patients with mitochondrial diseases have highly varied manifestations and can thus present to physicians in practically any branch of medicine. A correct diagnosis is the prerequisite for genetic counseling and for the initiation of personalized treatment.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a DNA, Mitochondrial
|2 NLM Chemicals
650 _ 2 |a Adult
|2 MeSH
650 _ 2 |a DNA, Mitochondrial: genetics
|2 MeSH
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Mitochondrial Diseases: diagnosis
|2 MeSH
650 _ 2 |a Mitochondrial Diseases: genetics
|2 MeSH
650 _ 2 |a Mitochondrial Diseases: therapy
|2 MeSH
650 _ 2 |a Optic Atrophy, Hereditary, Leber
|2 MeSH
650 _ 2 |a Quality of Life
|2 MeSH
700 1 _ |a Priglinger, Claudia
|b 1
700 1 _ |a Yilmaz, Ali
|b 2
700 1 _ |a Kornblum, Cornelia
|b 3
700 1 _ |a Distelmaier, Felix
|b 4
700 1 _ |a Prokisch, Holger
|b 5
773 _ _ |a 10.3238/arztebl.m2021.0251
|g Vol. 118, no. 44
|0 PERI:(DE-600)2406159-1
|n 44
|p 741-748
|t Deutsches Ärzteblatt international
|v 118
|y 2021
|x 1866-0452
856 4 _ |u https://pub.dzne.de/record/163395/files/DZNE-2022-00157_Restricted.pdf
856 4 _ |u https://pub.dzne.de/record/163395/files/DZNE-2022-00157_Restricted.pdf?subformat=pdfa
|x pdfa
909 C O |p VDB
|o oai:pub.dzne.de:163395
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 0
|6 P:(DE-2719)2810704
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2021
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2021-01-27
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2021-01-27
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b DTSCH ARZTEBL INT : 2021
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2022-11-18
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2022-11-18
915 _ _ |a IF >= 5
|0 StatID:(DE-HGF)9905
|2 StatID
|b DTSCH ARZTEBL INT : 2021
|d 2022-11-18
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 0
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a UNRESTRICTED


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21